HeartBeam, Inc. reports results for the quarter ended June 30 - Earnings Summary
HeartBeam, Inc. reports results for the quarter ended June 30 - Earnings Summary
HeartBeam, Inc. BEAT.OQ reported a quarterly adjusted loss of 10 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -15 cents. The mean expectation of four analysts for the quarter was for a loss of 9 cents per share. Wall Street expected results to range from -11 cents to -8 cents per share.
Reported revenue was zero; analysts expected $80.00 thousand.
HeartBeam, Inc.'s reported EPS for the quarter was a loss of 10 cents.
The company reported a quarterly loss of $5.04 million.
HeartBeam, Inc. shares had fallen by 23.7% this quarter and lost 76.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 12.2% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for HeartBeam, Inc. is $3.25, about 82.4% above its last closing price of $0.57
This summary was machine generated from LSEG data August 13 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.09 | -0.10 | Missed |
Mar. 31 2026 | -0.14 | -0.12 | Beat |
Dec. 31 2025 | -0.14 | -0.14 | Met |
Sep. 30 2025 | -0.13 | -0.15 | Missed |
Recent news on HeartBeam
See all newsBrief: Heartbeam Receives FDA Breakthrough Device Designation For Heart Attack Assessment
Brief: HeartBeam Will Not Build Large Commercial Organization For Arrhythmia Indication
Brief: Heartbeam, Inc. Enters Into At-The-Market Equity Offering Sales Agreement For Up To $25 Million In Common Stock
HeartBeam, Inc. reports results for the quarter ended June 30 - Earnings Summary
HeartBeam Q2 loss per share narrows; co lowers FY net operating cash outflow guidance